In support of targeting PARP14 to treat cancer, an inhibitor of PARP14, RBN012759, was shown to lead to an inflammatory response in tumour explants, similarly to that induced by immune checkpoint inhibitors (Schenkel et al., 2021). The gene discussed is PARP14; the disease is neoplasm.